Document Detail

Gender Differences in Drug Bioequivalence: Time to Rethink Practices.
MedLine Citation:
PMID:  23299647     Owner:  NLM     Status:  Publisher    
Currently, bioequivalence (BE) studies are carried out exclusively in males, assuming that intrasubject variabilities are similar between the sexes. This article challenges this hypothesis on the basis of available evidence and urges that studies of BE of sufficient power be undertaken in women also for all generic drugs aimed at women.Clinical Pharmacology & Therapeutics (2013); advance online publication 9 January 2013.doi:10.1038/clpt.2012.233.
G Koren; H Nordeng; S Macleod
Related Documents :
1266577 - Clonus depression by propranolol.
1204277 - Action of delta-9-tetrahydrocannabinol. an approach to the active metabolite hypothesis.
17340257 - Antihepatotoxic principles of artemisia capillaris buds1.
7277197 - The correlation between drug binding to the human erythrocyte and its hemolytic activity.
10357567 - Regulatory issues in the evaluation of antimetastatic and other novel anticancer therap...
21753867 - Nonsteroidal anti-inflammatory drug gastropathy: new avenues for safety.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-12-03
Journal Detail:
Title:  Clinical pharmacology and therapeutics     Volume:  -     ISSN:  1532-6535     ISO Abbreviation:  Clin. Pharmacol. Ther.     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2013-1-9     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0372741     Medline TA:  Clin Pharmacol Ther     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Motherisk Program, Division of Clinical Pharmacology/Toxicology, SickKids Hospital, University of Toronto, Toronto, Ontario, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Imaging of vulnerable plaques using near-infrared spectroscopy for risk stratification of atheroscle...
Next Document:  Class II treatment by extraction of maxillary first molars or Herbst appliance: dentoskeletal and so...